Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Autologous tumor-derived extracellular vesicle tropism refers to a drug delivery strategy that exploits the natural homing ability of extracellular vesicles (EVs) to return to their cell of origin (Kim et al., Nature Nanotechnology, 2017). Extracellular vesicles, such as exosomes, are nano-sized, membrane-bound particles secreted by cells that carry proteins, lipids, and nucleic acids for intercellular communication. Research has shown that EVs derived from tumor cells exhibit a unique tropism, or homotypic targeting, allowing them to preferentially accumulate in the tumor tissue from which they were derived (Garofalo et al., Journal of Controlled Release, 2019). This phenomenon is mediated by specific surface molecules, including integrins and tetraspanins, which interact with the extracellular matrix and receptors on the target tumor cells (Hoshino et al., Nature, 2015). By loading these autologous EVs with therapeutic agents like chemotherapeutics or RNA-based drugs, researchers aim to achieve highly specific delivery with reduced systemic toxicity and minimal immunogenicity. This approach is particularly promising for treating metastatic disease, as the vesicles can navigate the systemic circulation to find disseminated tumor cells. However, significant therapeutic challenges exist, including the potential for these vesicles to carry pro-tumorigenic signals or promote metastasis if the source cells are not carefully selected (Kalluri and LeBleu, Science, 2020). Furthermore, the complexity of isolating and standardizing autologous vesicles for clinical use remains a hurdle for widespread adoption.
Utilization of the innate homing ability of tumor-derived extracellular vesicles to deliver therapeutic payloads specifically to the site of the original tumor through surface-mediated recognition (e.g., integrins and adhesion molecules).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autologous tumor-derived extracellular vesicle (Autologous EV) (Autologous EV).